The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery

Lung Cancer Clinical Trial

Official title:

The Effect of Iloprost on Arterial Oxygenation and Shunt Fraction During One-lung Ventilation for Lung Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03936140
• Other study ID #: KC14MISI0880
• Status: Completed
• Phase: N/A
• Start date: January 4, 2018
• Est. completion date: October 24, 2018

Study information

• Verified date: May 2019
• Source: Seoul St. Mary's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

During one-lung ventilation in patients undergoing thoracic surgery, the persistent flow in the non-ventilated lung increases intrapulmonary shunt and decreases systemic arterial oxygenation. This prospective, randomized, double blind study was conducted to evaluate the effects of inhaled iloprost during one-lung ventilation on arterial oxygenation and shunt fraction during thoracic surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: October 24, 2018
• Est. primary completion date: October 24, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• elective video-assisted thoracoscopic surgery (VATS) lobectomy

• 20 < age < 75

• American Society of Anesthesiologists (ASA) classification I~III

Exclusion Criteria:

• ASA classification IV

• New York Heart Association (NYHA) class III~IV

• Severe obstructive lung disease / restrictive lung disease

• Pulmonary hypertension

• End-stage organ disease (i.e. hepatic failure, renal failure)

• Arrhythmia

• Previous history of thoracic surgery

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Drug:
• Inhaled iloprost
Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
• Distilled water
Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.

Locations

Country	Name	City	State
Korea, Republic of	Seoul St.Mary's Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Seoul St. Mary's Hospital	The Catholic University of Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PaO2(partial pressure of arterial oxygen)	ABGA	30 min after treatment
Primary	Pulmonary shunt fraction	Qs/Qt = (CcO2-CaO2) / (CcO2-CvO2)	30 min after treatment